Bayban’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bayban’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-100	Closed	-$1.59K	–	680
2025 Q4	$1.59K	Buy	+100	New	+$1.42K	﹤0.01%	553

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Bayban's AUPH Position: Q1 2026 in Review

Bayban sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2026, closing a stake of 100 shares — an estimated $1.59K sold.

Bayban first reported a position in AUPH in Q4 2025 and held it in 1 quarter. The position peaked at $1.59K in Q4 2025. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

Bayban reported no remaining Aurinia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Bayban sold 100 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $1.59K.
Bayban first reported a position in Aurinia Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Bayban's Aurinia Pharmaceuticals position peaked at $1.59K in Q4 2025.
259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Bayban's 13F filing for Q1 2026, filed 24 Apr 2026.